Effectiveness of Mindfulness-Based Relapse Prevention in Individuals with Substance Use Disorders: A Systematic Review

Eduardo Ramadas 1,2,3,*, Margarida Pedroso de Lima 1, Tânia Caetano 1,2,3, Jessica Lopes 3 and Maria dos Anjos Dixe 2

Faculty of Psychology and Educational Sciences, University of Coimbra, 3000-115 Coimbra, Portugal; mplima@fpcce.uc.pt (M.P. d.L.); taniasdcaetano@gmail.com (T.C.)
2 Center for Innovative Care and Health Technology (ciTechcare), Polytechnic of Leiria, 2410-541 Leiria, Portugal; maria.dixe@ipleiria.pt
3 VillaRamadas International Treatment Center, Research and Innovation Department, 2400-121 Leiria, Portugal; jesslopes.uc@gmail.com
* Correspondence: research@villaramadas.com

Abstract: Objectives: This systematic review aimed to understand the current state of the art about the effectiveness of mindfulness-based relapse prevention (MBRP) on individuals with substance use disorders (SUD), taking into account not only SUD variables (e.g., cravings, frequency of use) but also other relevant clinical variables (e.g., anxiety and depressive symptoms, quality of life).

Methods: A comprehensive search of electronic databases was conducted to identify studies that investigate MBRP interventions on individuals with SUD. Studies that met the inclusion criteria were synthesized and assessed using systematic review methods. Results: Thirteen studies were included in the present review. The methodological quality of the included studies was moderately strong. Nine studies (69.2%) used the traditional 16 h MBRP program. Six studies (46.1%) chose to use a co-intervention treatment ranging from the treatment as usual (TAU) to cognitive behavioral therapy. All but one study indicated that their interventions produced positive effects on at least one addiction outcome measure. None of the interventions were evaluated across different settings or populations. Conclusions: Despite some heterogeneity regarding the type of MBRP program used, results support the effectiveness of these interventions in the SUD population, especially in reducing cravings, decreasing the frequency of use, and improving depressive symptoms.

Keywords: mindfulness; MBRP; addiction; substance use disorder; systematic review; relapse prevention

1. Introduction

Substance use disorders (SUD) affect the lives of more than 35 million people worldwide according to 2019 data from the United Nations Office on Drugs and Crime [1]. A chronic disease, substance addiction is associated with significant costs not only for the individual but for society at large. It often starts with occasional substance use in a recreational context, followed by a progressive increase in frequency of use as the desired effects are diminished by habituation [2]. This process is mediated by genetic, developmental, and psychosocial factors that impact an individual’s relative vulnerability to the development of an addiction [3]. Although there are many different types of SUD, depending on the main substance of choice—with DSM-V offering diagnoses for the abuse of alcohol, cannabis, hallucinogens, opioids, and even caffeine, among others [4]—there are underlying mechanisms in addiction that appear to be common to all substances [3].

Given the prevalence and manifest individual and socioeconomic consequences of substance addiction, there has been a considerable effort by the scientific community to create and study effective treatments for SUD [5,6]. Despite this, relapse rates remain incredibly high, with data suggesting that more than two thirds of individuals return to...
substance use within a year of treatment [7]. The relapsing nature of substance addiction has made it clear that relapse prevention is an essential treatment component for long-term recovery, shifting attention to interventions that propose to address this need.

The most common intervention targeting relapse prevention is based on the identification of idiosyncratic high-risk situations that can increase the probability of relapse and the development of specific strategies that the individual can resort to when exposed to them [8]. However, recently, other types of interventions aiming to improve the effectiveness of SUD treatment and address relapse prevention have been emerging, as is the case with mindfulness-based interventions [9,10].

Mindfulness is a mental state that involves an awareness of the present moment and a non-judgmental posture towards internal and external phenomena. Practicing mindfulness has been shown to help regulate attention, cultivate acceptance, and develop the ability to observe inner experiences (thoughts, feelings, and physical sensations) without judgment [11,12]. In the context of addiction treatment, it can promote awareness of external and internal triggers for addictive behaviors and improve tolerance to uncomfortable emotional, cognitive, and physical experiences [13]. It can also have a significant effect on decreasing cravings after treatment [14].

Mindfulness-based relapse prevention (MBRP) is an intervention that integrates mindfulness meditation with traditional relapse prevention techniques. It has three main components: formal mindfulness practice, informal practice, and coping strategies. The formal practice includes body scan, sitting meditation (breath, body, thoughts, and emotions), mountain meditation, and loving-kindness meditation. The informal practice includes urge surfing, mindfulness of daily activities, SOBER breathing space, and mindful movement [15–17]. Some of the informal practices can be used as coping strategies due to the fact that they can help the patients cope with difficulties, emotional challenges, or stress [18]. As such, this last component intends to adapt informal practice into practical strategies the individuals can use in real-life situations.

The original MBRP program has a total of 16 h divided into 8 weekly sessions (2 h each) but can be adapted according to the target population and the researchers’ goals [19,20]. The sessions include mindfulness practices and exercises that aim to increase the individual’s awareness of internal (emotional and cognitive) and external (situational) cues related to substance use and help in the development of appropriate coping strategies [21].

The first three sessions of the program focus on raising the individual’s awareness of environmental triggers and reactions that may occur in response to them. The first session centers on the individual’s habits, which occur in autopilot mode; the second centers on increasing the awareness of triggers and cravings; and the third centers on the promotion of mindfulness practice in daily life. Sessions four, five, and six focus on mindfulness in the context of relapse prevention. The fourth session centers on the use of mindfulness in high-risk situations; the fifth session intends to teach acceptance and skillful action; and the sixth session centers on the concept of defusion, that is, the ability to see thoughts only as thoughts and not as reflections of reality. Finally, the last two sessions focus on social and environmental factors and have the goal of guiding the application of what was learned to everyday life [15,22].

The aim of this review was to evaluate the effectiveness of MBRP in individuals with SUD. Although the search conducted on the Web of Science and Cochrane Database of Systematic Reviews revealed the existence of a systematic review/meta-analysis looking into this same question [23], we considered that the interest this topic has gathered in recent years justified another review. It is not only likely but probable that in the four years that have passed since Grant et al. [23] conducted their review, new relevant studies have been added to the literature. Given the rapid growth of knowledge concerning this type of intervention, we also hope that more recent studies have taken into account some of the limitations found in their earlier counterparts.

To better understand the effectiveness of MBRP in this population, we considered the following questions:
I Do MBRP interventions lead to significant improvements in SUD variables (e.g., cravings, frequency of use) in individuals with SUD?
II Do MBRP interventions lead to significant improvements in other relevant clinical variables (e.g., anxiety, depression, quality of life) in individuals with SUD?
III How do MBRP interventions compare to other evidence-based interventions for individuals with SUD?

2. Materials and Methods

2.1. Research Strategy

This systematic review was not pre-registered, and the results should be considered exploratory.

Through the research performed on the Cochrane Central Register of Controlled Trials (CENTRAL), JBI Database of Systematic Reviews and Implementation Reports, Database of Promoting Health Effectiveness Reviews (DoPHER), Evidence for Policy and Practice Information and Coordinating Center (EPPI-Center), and PROSPERO International Prospective Register of Systematic Reviews, no systematic literature review was found after the year 2017.

Initially, a general search was carried out in Cochrane, Pubmed, and Web of Science, after which the terms used in the title and abstract of the articles were examined. In a second phase, using the identified keywords and descriptors, research was conducted on all databases included in this review (Table A1). Due to the multiplicity of concepts to describe the term (addiction) we used a global MeSH term in our research. In the last phase of the research, we used the bibliography of the selected studies to search for additional/complementary ones.

2.2. Study Screening and Selection

The inclusion criteria were developed based on the PICO system used to form the research question.

Inclusion criteria were studies that included participants with minimum age of 18 years (female or male) with diagnosis of substance use disorder (alcohol, opioids, cannabis, and/or stimulants). Regarding the intervention, studies that used the MBRP as an individual and/or complementary intervention tool were included in the present review. As for the comparator, all types of interventions were accepted, namely the TAU. As for outcomes of interest, we intend to investigate if the MBRP interventions are effective in this type of population based on indicators supported by other studies in the field [9,23].

We distinguished the following categories of study designs to be included in the present review: experimental designs (randomized controlled trials [RCT]) and quasi-experimental studies. Studies written in English, Spanish, and Portuguese were included.

Exclusion criteria were omission of diagnosis of substance use disorder, intervention without recourse to the MBRP, inclusion of a population under 18, study design other than experimental or quasi-experimental, and studies written in a language other than Portuguese, English, or Spanish. The differences found between reviewers during this process were resolved through dialogue and, when necessary, through a third reviewer.

2.3. Data Extraction and Quality Assessment

Data were extracted by two independent reviewers, with emphasis on specific details related to the specificity of the population, the type of co-intervention used, the type of comparator, the study design, and relevant results underlining the objective and conducting question of the review.

In order to minimize the risk of bias among the selected studies, the Joanna Briggs Institute Checklist for Randomized Controlled Trials was used for the critical analysis of the RCT included. For the analysis of the quasi-experimental studies, the Checklist for Quasi-Experimental Studies was used. To examine the methodological quality of the included studies, the “Study Appraisal Checklist” was used. This checklist is composed
of 27 items divided into 5 categories (reporting, external validity, bias, confounding, and power) with a higher score being equivalent to a higher methodological quality. According to the checklist development study [24] and the other systematic review [25] using this same instrument, the cut-off point of 14 was used as a guideline to define low/good methodological quality of the studies.

The differences found between reviewers during this process were resolved through dialogue and, when necessary, through a third reviewer. The risks of bias for each type of study included were examined in detail (e.g., selection bias). An individual assessment of the risk of bias was performed for each of the included studies. These results are reported in the Methodological Quality section.

2.4. Data Analysis

The influence of the interventions carried out using the MBRP and its effects on the population was described in a narrative format for each of the included interventions. A description was made taking into account the year in which the studies were carried out.

The data analysis was described based on the following topics: aim of the study, type of MBRP program used, the researcher administrator, type of co-intervention and comparator used, the existence of follow-up, and the respective results. Regarding the results, they were presented taking into account the variables of interest, namely the relapse rate, frequency of use, cravings/desire to use, and depression and anxiety symptoms.

3. Results

3.1. Search

A total of 215 articles were identified as potentially relevant to the present review (Figure 1). Of these, 42 were excluded due to being duplicate studies. The titles and abstracts of the remaining articles were examined taking into account the inclusion and exclusion criteria, and 143 more studies were excluded. From the 30 studies selected for the full text analysis, 17 were excluded for not meeting all the inclusion criteria (seven did not mention a diagnosis of substance use disorder, six did not have an experimental study design, three did not present the outcomes found, and one had a different population). Of the 13 studies included, 10 (76.9%) are RCT and 3 (23.0%) are quasi-experimental studies without a control group.

3.2. Characteristics of Included Studies

All the studies included were written in English and, as previously mentioned, published between 2016 and 2020. We decided to include studies since 2016, as some studies published this year may not have been considered in the previous review. Regarding the country of origin, seven studies (53.8.5%) were carried out in the United States [19,20,26–30], four (30.7%) in Iran [31–34], and two (15.3%) in France [22,35]. The sample sizes ranged from 6 to 191. The type of population used was different among the studies: four (30.7%) used only individuals with alcohol use disorder [19,20,22,29], three (23.0%) included individuals with substance use disorder related to methadone [31–33], and two (15.3%) used individuals with a stimulant and opioid use disorder, respectively [26,30]. On the other hand, three studies (23.0%) had heterogeneous samples, including individuals with various substance use disorders [28,34,35]. One (7.6%) of the studies did not provide information on the characteristics of the sample used [27]. Table A2 presents the synthesized information of the included studies.

3.3. Methodological Quality

The design of the included studies consisted of 10 (76.9%) RCT [19,20,26–29,31–34] and 3 (23.0%) quasi-experimental studies [22,30,35]. The methodological quality of the studies according to the Study Appraisal Checklist varied between 10 and 25 (maximum = 28) with an average of 17.3 [SD = 3.9]. The studies with the lowest and highest quality had values of 37.0% and 92.5%, respectively. Only two studies were categorized as being of
low methodological quality [22,35]. A decision was made to include these studies with
the goal of considering a greater variety of study designs. The specific methodological
quality flaws that were found in the great majority of the included studies are related to the
distribution of the main confounders in each group (n = 8), the adverse events (n = 7), the
representativeness of the sample included (n = 12), the lack of blindness of the assessors
(n = 10), and no calculation of the sample power (n = 9). Table A3 displays the score of
each study.

![PRISMA Flow Diagram](image)

**Figure 1. PRISMA Flow Diagram.**

With regard to the methodological quality of the RCT included, the questions (Q2, Q4,
Q5, and Q6) of the used checklist required refinement in the majority of the studies, only
being clear in three of them (Table A4). These questions clarify, respectively, whether the
allocation to the treatment group was concealed (Q2), whether the participants were blind
to the assigned condition (Q4), whether the researchers who applied the intervention were
blind to the treatment assignment (Q5), and whether the outcome assessors were blind to
the treatment assignment (Q6).

In the study conducted by Glasner et al. (2017; [26]), the allocation into the respective
groups was concealed from participants but not from the practitioners. On the other hand,
in the study by Witkiewitz et al. (2019; [19]), although both participants and practitioners
were blinded to the assigned condition, the researchers responsible for analyzing the
outcomes were not. Regarding the reliability of the outcomes and the statistics used, the
studies by Yaghubi et al. (2017; [32]) and Zgierska et al. (2017; [20]) were not clear about
either the statistical analyses used or the outcome measures considered. The study by
Zemestani and Ottaviani (2016; [34]) presented greater objectivity and clarity in all the procedures performed.

Regarding the methodological quality of the quasi-experimental studies included, seven of the nine questions included in the checklist used were clear in all studies (Table A5). These questions referred to the clarity of the study with regard to cause and effect (Q1), whether the participants were included in any type of comparison (Q2), if there was a control group (Q4), if there were multiple evaluations of results before and after the intervention (Q5), if follow-up was performed (Q6), whether the results of the included participants were evaluated in the same way (Q7), and whether appropriate statistical tests/procedures were used (Q9). In the study of Von Hammerstein et al. (2019; [22]), it is not clear if the participants received other intervention in combination with the intervention of interest. In the studies by Zullig et al. (2018; [30]) and Biseul et al. (2017; [35]), it is not clear how the reliability of the results measured was guaranteed. Neither study presented a control group.

3.4. Intervention Characteristics

Despite the heterogeneity of the included studies, it was found that nine used the traditional 16 h MBRP program [22,27,28,30–35]. The remaining four chose to use a version of the program adapted to the population and/or study objective [19,20,26,29]. There was also some diversity between studies regarding the length of the intervention program and the length of the sessions. While the majority of the studies (84.6%) used the standard 16 h intervention, with a duration of 120 min for each session [20,22,27–35], two studies chose to adapt the MBRP program according to the desired intervention characteristics and/or time available for it. One study (7.6%; [26]) used the 10 h MBRP program, with each session having a duration of 75 min. Another study (7.6%; [19]) chose to use a 12 h program, with each session having a duration of 90 min.

At the intervention level, most studies chose to use a co-intervention treatment. Three studies (23.1%) used medication-assisted treatment (e.g., methadone-therapy) as co-intervention [30–32], with two of those also using it as a comparator [30,31]; two (15.3%) used TAU as both co-intervention and comparator [20,29]; one (7.6%) used transcranial direct current stimulation as a co-intervention and a sham version of the same intervention as a comparator [19]; one (7.6%) study chose a contingency management intervention that was also a comparator together with a health education intervention [26]; and one study (7.6%) chose to use cognitive behavior therapy as a co-intervention and did not use a comparator [35].

The remaining studies did not use any type of co-intervention, with one (7.6%) using only TAU as a comparator [34], one (7.6%) using a traditional relapse prevention intervention [27], and another (7.6%) using both TAU and relapse prevention [28] as co-intervention interventions. Two studies (15.3%) chose not to use either a co-intervention or a comparator [22,33].

All but one (7.6%) study [30] used follow-up assessments in order to analyze the consistency and reliability of the outcomes obtained.

Table A6 presents a summary of the results described.

3.5. Intervention Outcomes

Of the 13 included studies, only one did not report significant improvements in at least one of the outcome measure [29]. The studies by Witkiewitz et al. (2019; [19]), Roos et al. (2020; [28]), and Greenfield et al. (2018; [27]) presented a significant decrease in the substance use frequency of the participants in the MBRP group: (SE = −0.535 (0.16), \( p = 0.001 \)), (IRR = 0.000003, CI (−0.032, 0.021), and (IRR = 0, 95% CI: 0,0). Another three studies [31,33,34] showed a significant reduction in the desire to use following the MBRP intervention: (F (2,144) = 35.90, \( p < 0.0001 \)) and (F = 374.22, \( p = 0.00 \)). Moreover, Zemestani and Ottaviani (2016; [34]) also reported a beneficial impact of MBRP on anxiety (F (2,144) = 43.96,
p < 0.0001) and depressive (F (2,144) = 30.73, p < 0.0001) symptoms. Two other studies found similar results regarding the significant improvement of depressive complaints [22,35].

Lastly, two studies presented significant and positive changes on impulsivity levels [32] and quality of life [33].

4. Discussion

The objective of the present review was to evaluate the effectiveness of MBRP on individuals with SUD. A majority of the included studies [19,22,26–28,30–35] found significant improvements in at least one SUD or clinical variable following an MBRP intervention. This was true not only for studies that used the original MBRP program but also for those that chose a modified version (e.g., different program length or session duration).

Regarding the impact of MBRP on SUD variables, the results indicate that participants that received the intervention had a significant decrease in frequency of use, both measured by days of heavy drinking [19,22,27,28] and number of drinks per day [19] for alcohol and number of using days/substance misuse for other substances [27,35]. There was also a significant decrease in cravings/desire to use [31,33,34], withdrawal symptoms [31], and probability of relapse [32].

Concerning other clinical variables, the results suggest that participants who received an MBRP intervention saw a significant decrease of anxiety [22,34] and depression [22,26,30,34,35] symptoms as well as reduced impulsivity levels [32]. Moreover, they showed a significant improvement in quality of life [33] and coping capacity over time [26]. These findings seem to be congruent with the subjective experience of the participants which, as found by Zgierska et al. (2017; [20]), presented an overall satisfaction with the intervention and believed it to be helpful for their disorder.

Only three studies [27,28,34] chose to apply the MBRP program without a co-intervention while providing a comparator group. Two other studies used TAU as a co-intervention and comparator [20,29]. This made it difficult to properly compare the effectiveness of MBRP against that of other evidence-based treatments. Still, the results are relevant to understand if new knowledge on the relative effectiveness of MBRP has been created since the last systematic review conducted by Grant et al. [23].

Supporting the conclusions from the previous review [23], Zgierska et al. [29] found that MBRP plus TAU was not more effective than TAU in individuals with alcohol dependence. Even though there were no significant group differences, it should be noted that individuals from both groups showed favorable outcomes. On the other hand, Roos et al. [28] and Zemestani and Ottaviani [34], who also compared MBRP with TAU, found different results. Roos et al. [28] reported an interaction by affective symptoms that predicted increases in approach coping, which in turn led to more favorable substance use related outcomes (i.e., fewer heavy drinking days and substance use problems at 12 months). The mediator effect of increased approach coping was only found for individuals with high base-line affective symptoms (as opposed to low or moderate). Similarly, Zemestani and Ottaviani [34] found that MBRP was significantly more effective than TAU in reducing rates of depression, anxiety, and cravings in individuals with SUD and comorbid depression. Finally, Greenfield et al. [27] compared the current most used form of relapse prevention [8] with MBRP and found significant differences regarding the decrease of frequency of use.

The results from the studies by Roos et al. [28] and Zemestani and Ottaviani [34] are particularly interesting. They indicate that MBRP may be especially useful for individuals who present SUD in comorbidity with severe psychiatric symptomatology, namely those with affective disorders. This could be explained by the impact mindfulness has been shown to have in facilitating emotional regulation. Hölzel et al. [36], for example, have proposed that the effects of mindfulness are a result of changes in mental and brain functions pertaining to, among other self-regulatory systems, attention and emotional regulation. Similarly, Vago and Silbersweig [37] suggested that changes in self-regulation and self-awareness resulting from mindfulness reflect modulation in neurocognitive networks associated with various dimensions, including emotional regulation. Some authors
(e.g., [38,39]) have even argued that mindfulness might employ a unique strategy of emotional regulation based on bottom-up systems (contrary to cognitive reappraisal, which relies on top-down systems). Bottom-up pathways are thought to be responsible for emotional processing (generation of arousal and affect; [40]) and have been linked to some limbic regions and the striatum [41].

Interestingly, bottom-up along with top-down processes have also been hypothesized as possible mediators to the effects of mindfulness practice on SUD [40]. This is at least in part explained by the role these and associated pathways are proposed to play on the reactivity to drug stimuli, drug cravings, and relapse. Despite their believed relevance, so far these pathways have barely been researched.

As with all studies, the present review has limitations that need to be considered when interpreting its results. It is important to highlight the presence of methodological weaknesses in some of the included studies, such as a reduced sample size in those using a quasi-experimental design [22,30,35]. Given that these weaknesses can skew the results obtained, it is not possible generalize them and conclude the effectiveness of the intervention under study. Another aspect to consider is the significant heterogeneity found between studies in relation to the main objectives, target population, and type of intervention, which invalidated the option of conducting a meta-analysis. Beyond the characteristics of the studies included, another limitation of this systematic review was the reduced number of databases used for the article search. A broader search might have led to the discovery and inclusion of more studies and, as result, a more complete account of the current state of the art about this subject matter.

In conclusion, we believe the results of the present review indicate that MBRP has a significant positive impact on various substance use and clinical variables. Moreover, even though we could not properly evaluate the comparative effectiveness of MBRP in relation to other evidence-based treatments, the results suggest that this intervention may be of particular value to the treatment of individuals with SUD and comorbid psychiatric symptomatology. Future studies should not only continue to investigate the effectiveness of MBRP in individuals with SUD (with and without psychiatric comorbidity) but also explore possible mediating variables that may allow for a better understanding of it. Furthermore, we believe that future research into the effectiveness of MBRP would greatly benefit from considering neural measures in order to deepen the knowledge of the neural circuit mechanisms involved in the practice of mindfulness and how these relate to relapse prevention. There were few studies that considered neural responses in their results, with only one study of interest in this area [19].

Author Contributions: Conceptualization, E.R., M.P.d.L., and M.d.A.D.; methodology, E.R., M.P.d.L., M.d.A.D., and T.C.; validation, E.R., M.P.d.L., and M.d.A.D.; formal analysis, E.R., M.P.d.L., M.d.A.D., and T.C.; investigation, E.R., M.P.d.L., M.d.A.D., and T.C.; resources, E.R.; data curation, E.R. and T.C.; writing—original draft preparation, E.R., M.P.d.L., M.d.A.D., T.C., and J.L.; writing—review and editing, E.R., M.P.d.L., M.d.A.D., T.C., and J.L.; writing—review and editing, M.P.d.L., M.d.A.D., T.C., and J.L.; supervision, M.P.d.L. and M.d.A.D.; project administration, E.R.; funding acquisition, M.d.A.D. All authors have read and agreed to the published version of the manuscript.

Funding: The authors received no financial support for the research and publication of this article.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: Eduardo Ramadas is the Executive and Clinical Director of VillaRamadas International Treatment Centre, an institution that provides addiction treatment. Even though the specific therapeutic intervention analyzed in this systematic review (MBRP) does not feature in the center’s current therapeutic program, there is the intention of studying its effectiveness with the center’s population in the future.
Abbreviations

MBRP  Mindfulness-Based Relapse Prevention
RCT  Randomized Controlled Trials
SUD  Substance Use Disorders
TAU  Treatment as Usual

Appendix A

Table A1. Research terms used in databases.

| Database                                      | Research Terms                                                                 |
|-----------------------------------------------|--------------------------------------------------------------------------------|
| Cochrane, Pubmed, Web of Science e Scopus     | “Mindfulness-Based Relapse Prevention” OR “MBRP” AND “substance related disorder” OR “Substance dependency” OR “alcohol induced disorders” OR “Chemical Dependency” OR “substance addiction” OR “drug use disorder” OR “street drugs” |

Table A2. Characteristics of the included studies.

| Study                                      | Country | Participants | Substance Issue                                      |
|--------------------------------------------|---------|--------------|-----------------------------------------------------|
| Roos, Bowen, and Witkiewitz, 2020 [28]     | USA     | 286 participants—38.44 years.; 71.8% male           | Substances (alcohol, cocaine, opioids, among others) |
| Zgierska et al., 2019 [29]                 | USA     | 112 Participants—41 years.; 56% male                 | Alcohol                                            |
| Foroushani, 2019 [31]                      | Iran    | 55 participants—NP                                   | Methadone                                          |
| Witkiewitz et al., 2019 [19]               | USA     | 84 participants—52.27 years.; 59.5% male             | Alcohol                                            |
| Von Hammerstein et al., 2019 [22]          | France  | 52 participants—49.4 years.; 60% male                | Alcohol                                            |
| Yaghubi and Zargar, 2018 [33]              | Iran    | 70 participants—30.26 years.; 100% male              | Methadone                                          |
| Greenfield et al., 2018 [27]               | USA     | 191 participants—39.04 years.; 71% male              | NP                                                 |
| Zgierska, Shapiro, Burzinski, Lerner, and Goodman-Strenske, 2017 [20] | USA     | 123 participants—41.2 years.; 56.9% male             | Alcohol                                            |
| Yaghubi, Zargar, and Akbari, 2017 [32]     | Iran    | 70 participants—31.73 years.; 100% male              | Methadone                                          |
| Zullig et al., 2018 [30]                   | USA     | 16 participants—36 years.; 37.5% male                | Opioid                                             |
| Glasner et al., 2017 [26]                  | USA     | 63 participants—45.3 years.; 71% male                | Stimulants                                          |
| Zemestani and Ottaviani, 2016 [34]         | Iran    | 74 participants—30.1 years.; 79.7% male              | Substances (methamphetamine, cocaine, heroin, among others) |
| Biseul, Icick, Seguin, Bellivier, and Scott, 2017 [35] | France  | 6 participants—52.5 years.; 67% male                 | Substances (alcohol, cannabis, heroin, among others) |

Table A3. Methodological quality of the included studies.

| Study                                      | Reporting (0–11) | External Validity (0–3) | Bias (0–7) | Confounding (0–6) | Power (0,1) | Overall (0–28) |
|--------------------------------------------|------------------|-------------------------|------------|-------------------|-------------|----------------|
| Roos, Bowen, and Witkiewitz, 2020 [28]     | 6                | 1                       | 3          | 4                 | 0           | 14             |
| Zgierska et al., 2019 [29]                 | 9                | 1                       | 4          | 4                 | 0           | 18             |
| Foroushani, 2019 [31]                      | 6                | 1                       | 5          | 3                 | 0           | 15             |
| Witkiewitz et al., 2019 [19]               | 10               | 1                       | 7          | 6                 | 1           | 25             |
| Von Hammerstein et al., 2019 [22]          | 7                | 1                       | 3          | 2                 | 0           | 13             |
| Yaghubi and Zargar, 2018 [33]              | 7                | 2                       | 3          | 4                 | 1           | 17             |
| Greenfield et al., 2018 [27]               | 10               | 1                       | 6          | 5                 | 0           | 22             |
| Zgierska et al., 2017 [20]                 | 9                | 1                       | 6          | 4                 | 1           | 21             |
### Table A3. Cont.

| Study                                      | Reporting (0–11) | External Validity (0–3) | Bias (0–7) | Confounding (0–6) | Power (0,1) | Overall (0–28) |
|--------------------------------------------|------------------|-------------------------|------------|-------------------|-------------|----------------|
| Yaghubi, Zargar, and Akbari, 2017 [32]    | 7                | 1                       | 5          | 5                 | 1           | 19             |
| Glasner et al., 2017 [26]                 | 8                | 1                       | 5          | 4                 | 0           | 18             |
| Zullig et al., 2018 [30]                  | 7                | 1                       | 3          | 3                 | 0           | 14             |
| Biseul et al., 2017 [35]                  | 5                | 1                       | 1          | 3                 | 0           | 10             |
| Zemestani and Ottaviani, 2016 [34]        | 8                | 3                       | 5          | 4                 | 0           | 20             |

### Table A4. Evaluation of methodological quality of included randomized controlled trials.

| Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 | Q10 | Q11 | Q12 | Q13 |
|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|
| -  | ?  | -  | ?  | +  | +  | -  | -  | -  | -   | -   | -   | ?   |
| -  | +  | -  | +  | +  | +  | -  | -  | -  | -   | -   | -   | -   |
| -  | ?  | -  | +  | +  | +  | -  | -  | -  | -   | ?   | -   | -   |
| ?  | ?  | -  | ?  | ?  | ?  | -  | -  | -  | -   | -   | -   | +   |
| ?  | ?  | -  | ?  | ?  | ?  | -  | -  | -  | -   | -   | -   | ?   |
| ?  | ?  | -  | ?  | ?  | ?  | -  | -  | -  | -   | -   | -   | ?   |
| -  | ?  | -  | ?  | ?  | ?  | -  | -  | -  | -   | ?   | ?   | ?   |
| -  | ?  | -  | ?  | ?  | ?  | -  | -  | -  | -   | -   | -   | ?   |
| -  | -  | -  | -  | +  | +  | -  | -  | -  | -   | -   | -   | -   |

Note. Low risk of bias (-), unclear risk of bias (?), risk of bias (+).

### Table A5. Evaluation of methodological quality of included quasi-experimental studies.

| Q1 | Q2 | Q3 | Q4 | Q5 | Q6 | Q7 | Q8 | Q9 |
|----|----|----|----|----|----|----|----|----|
| -  | -  | ?  | +  | -  | -  | -  | -  | -  |
| -  | -  | +  | +  | -  | -  | -  | -  | ?  |
| -  | -  | +  | +  | -  | -  | -  | -  | ?  |
Table A6. Summary of included studies.

| Study                          | Aim                                                                 | MBRP Program | MBRP Full-Length | MBRP Time p/Session | MBRP Provider | Co-Intervention | Comparator       | Follow-Up          | Outcomes                                                   |
|--------------------------------|----------------------------------------------------------------------|--------------|------------------|--------------------|---------------|-----------------|-----------------|------------------|------------------------------------------------------------|
| Roos, Bowen, and Witkiewitz, 2020 [28] | Investigate if changes coping may explain the effects of MBRP        | Standard (8 sessions) | 16 h             | 120 min            | Clinical psychologists | No co-intervention | Relapse prevention or TAU | 2nd, 4th, 6th, and 12th month | MBRP showed significant results on heavy drinking days and increased coping over time |
| Zgierska, 2019 [29]            | Anayze the effects of MBRP on alcohol use disorder                  | MBRP-A (8 sessions) | 16 h             | 120 min            | Therapist with certified mindfulness course | Usual-Care (comparator) | Usual-Care | 8th and 26th week | No significant results were found                          |
| Foroushani, 2019 [31]          | Investigate the impact of the MBRP intervention on cravings, lapse, and mindfulness fostering | Standard (8 sessions) | 16 h             | 120 min            | NP             | No co-intervention | No-comparator | 1st, 2nd, and 3rd month | MBRP showed significant reduction in the desire to use and in the symptoms of dysphoria and withdrawal |
| Witkiewitz et al., 2019 [19]   | Evaluate the efficacy of MBRP combined with active or sham tDCS      | MBRP modified version (8 sessions) | 12 h             | 90 min             | Trained therapists in MBRP | Transcranial direct current stimulation (tDCS) | Sham tDCS + MBRP | 2nd, 3rd, 4th and 6th month following baseline | MBRP showed reduction in the nº of drinks per day and a lower percentage of heavy drinking days over time |
| Von Hammerstein et al., 2019 [22] | Evaluate the feasibility and preliminary efficacy of the MBRP in alcohol use disorder | Standard (8 sessions) | 16 h             | 120 min            | NP             | No co-intervention | No-comparator | 6th month        | MBRP showed reduction on depression and anxiety levels and on heavy drinking days |
| Yaghubhi and Zargar, 2018 [33] | Evaluate the effectiveness of MBRP on QOL and cravings               | Standard (8 sessions) | 16 h             | 120 min            | NP             | No co-intervention | No-comparator | 2nd month         | MBRP showed significant results on reducing cravings and showed improvements on QoL |

QOL = Quality of Life
| Study                        | Aim                                                                 | MBRP Program   | MBRP Full-Length | MBRP Time p/Session | MBRP Provider                                                                 | Co-Intervention | Comparator       | Follow-Up     | Outcomes                                                                 |
|-----------------------------|----------------------------------------------------------------------|----------------|------------------|---------------------|--------------------------------------------------------------------------------|-----------------|-----------------|---------------|--------------------------------------------------------------------------|
| Greenfield et al., 2018 [27] | Evaluate race/ethnicity and racial/ethnicity group composition has moderators of MBRP; how the relationship between individual minority status vs. group composition can moderate treatment effects | Standard (8 sessions) | 16 h             | 120 min             | Clinical psychologists in a doctoral training program with master degree | No co-intervention | Relapse prevention (RP) | 12th month    | MBRP showed better results in both white and racial/ethnic minorities in substance use; MBRP white group showed a significant reduction on heavy drinking days at 12 months; minorities in the MBRP group showed a significant reduction in drug use days at 12 months |
| Zgierska, Shapiro, Burzinski, Lerner, and Goodman-Strenski, (2017) [20] | Describe the implementation and findings related to fidelity monitoring of MBRP | MBRP-A (8 sessions) | 16 h | 120 min | Trained therapists in Mindfulness Meditation (MM) | Usual-Care (comparator) | Usual-Care | 26th week | Participants revealed overall satisfaction with the intervention, classifying it as helpful for their disorder |
| Yaghubi, Zargar, and Akbari, 2017 [32] | Compare the effectiveness of MBRP vs. TAU on impulsivity and relapse | Standard (8 sessions) | 16 h | 120 min | Clinical Psychologist | No co-intervention | TAU | 2nd month | MBRP showed significant reductions on impulsivity levels and on the probability of relapse |
| Zullig et al., 2018 [30] | Compare the effectiveness of MBRP in an outpatient setting | Standard (8 sessions) | 16 h | 120 min | NP | Medication-assisted treatment (MAT) | MAT | No follow-up | MBRP showed significant reductions in depression |
| Study | Aim | MBRP Program | MBRP Full-Length | MBRP Time p/Session | MBRP Provider | Co-Intervention | Comparator | Follow-Up | Outcomes |
|-------|-----|--------------|-----------------|-------------------|--------------|----------------|------------|----------|---------|
| Glasner, 2017 [26] | Investigate the efficacy and outcomes of MBRP in comparison to a health education (HE) control | MBRP modified version (8 sessions) | 10 h | 75 min | Therapist with certified mindfulness course | Contingency Management (CM) | HE + CM | 1st month | MBRP has demonstrated significant results in improving depressive symptoms and general psychiatric severity |
| Zemestani and Ottaviani, 2016 [34] | Examine the efficacy of MBRP vs. TAU in reducing cravings and depressive, anxious symptomatology | Standard | 16 h | 120 min | Clinical Psychologist with PhD | No co-intervention | TAU | 2nd month | MBRP showed significant results in reducing depression, cravings, and anxiety |
| Biseul, Icick, Seguin, Bellivier, and Scott, 2017 [35] | Evaluate the feasibility and acceptability of HABIT (CBT + MBRP) | Standard | 16 h | 120 min | Psychologist trained in MBCT | Cognitive Behavioural therapy (CBT) | No-comparator | After intervention | HABIT showed significant results in reducing depressive symptoms and substance misuse |

Note. NP: not provided; HE: health education; TAU: treatment as usual.
References

1. United Nations Office on Drugs and Crime. (n.d.) World Drug Report 2019: 35 million People Worldwide Suffer from Drug Use Disorders While Only 1 in 7 People Receive Treatment. Available online: https://www.unodc.org/unodc/en/frontpage/2019/June/world-drug-report-2019.-35-million-people-worldwide-suffer-from-drug-use-disorders-while-only-1-in-7-people-receive-treatment.html (accessed on 5 August 2021).

2. Mayo Clinic. Drug Addiction (Substance Use Disorder). 2017. Available online: https://www.mayoclinic.org/diseases-conditions/drug-addiction/symptoms-causes/syc-20565112?p=1 (accessed on 8 August 2021).

3. Volkow, N.D.; Michaelides, M.; Baler, R. The neuroscience of drug reward and addiction. Physiol. Rev. 2019, 99, 2115–2140. [CrossRef] [PubMed]

4. DSM 5 Criteria for Substance Use Disorders. Available online: https://www.verywellmind.com/dsm-5-criteria-for-substance-use-disorders-21926 (accessed on 5 August 2021).

5. McNeely, J.; Troxel, A.B.; Kunins, H.V.; Shelley, D.; Lee, J.D.; Walley, A.; Weinstein, Z.M.; Billings, J.; Davis, N.J.; Marcello, R.K.; et al. Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment. Addict. Sci. Clin. Pract. 2019, 14, 5. [CrossRef] [PubMed]

6. Tai, B.; Volkow, N.D. Treatment for Substance Use Disorder: Opportunities and Challenges under the Affordable Care. Act. Soc. Work Public Health 2013, 28, 165–174. [CrossRef] [PubMed]

7. Brandon, T.H.; Virdine, J.I.; Litvin, E.B. Relapse and relapse prevention. Annu. Rev. Clin. Psychol. 2007, 3, 257–284. [CrossRef] [PubMed]

8. Marlatt, G.A.; Donovan, D.M. (Eds.) Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors, 2nd ed.; The Guilford Press: New York, NY, USA, 2005.

9. Li, W.; Howard, M.O.; Garland, E.L.; McGovern, P.; Lazar, M. Mindfulness treatment for substance misuse: A systematic review and meta-analysis. J. Subst. Abus. Treat. 2017, 75, 62–96. [CrossRef] [PubMed]

10. Priddy, S.E.; Howard, M.O.; Hanley, A.W.; Riquino, M.R.; Friberg-Felsted, K.; Garland, E.L. Mindfulness meditation in the treatment of substance use disorders and preventing future relapse: Neurocognitive mechanisms and clinical implications. Subst. Abus. Rehabil. 2018, 9, 103–114. [CrossRef] [PubMed]

11. Khanna, S.; Greeson, J.M. A narrative review of yoga and mindfulness as complementary therapies for addiction. Complement. Ther. Med. 2013, 21, 244–252. [CrossRef]

12. Crane, R.S.; Brewer, J.; Feldman, C.; Kabat-Zinn, J.; Santorelli, S.; Williams, J.M.G.; Kuyken, W. What defines mindfulness-based programs? The warp and the weft. Psychol. Med. 2014, 47, 990–999. [CrossRef]

13. Leff, J.S.; Riba, M.O. Mindfulness-based relapse prevention: History, mechanisms of action, and effects. Mindfulness 2015, 6, 151–158. [CrossRef]

14. Garland, E.L.; Howard, M.O. Mindfulness-based treatment of addiction: A current state of the field and envisioning the next wave of research. Adv. Alcohol. Subst. Abus. 2015, 34, 1563–1571. [CrossRef]

15. Witkiewitz, K.; Bowen, S.; Douglas, H.; Hsu, S.H. Mindfulness-based relapse prevention for substance craving. Addict. Behav. 2013, 38, 1563–1571. [CrossRef]

16. Bowen, S.; Witkiewitz, K.; Clifasefi, S.L.; Grow, J.; Chawla, N.; Hsu, S.H.; Carroll, H.A.; Harrop, E.; Collins, S.E.; Lustyk, M.K.; et al. Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders. JAMA Psychiatry 2014, 71, 547–556. [CrossRef]

17. Penberthy, J.K.; Konig, A.; Gioia, C.J.; Rodriguez, V.M.; Starr, N.L.; Meese, W.; Worthington-Stoneman, D.; Kersting, K.; Natanya, E. Mindfulness-based relapse prevention: History, mechanisms of action, and effects. Mindfulness 2015, 6, 151–158. [CrossRef]

18. Weber, B.; Slaa, L.; Gex-Fabry, M.; Docter, A.; Gorwood, P.; Chalder, T.; Bondolfi, G.; Jermann, F.; Aubry, J.M.; Mirabel-Sarron, C. Self-reported long-term benefits of mindfulness-based cognitive therapy in patients with bipolar disorder. J. Altern. Complement. Med. 2017, 23, 534–540. [CrossRef]

19. Witkiewitz, K.; Stein, E.R.; Votaw, V.R.; Wilson, A.D.; Roos, C.R.; Gallegos, S.J.; Clark, V.P.; Claus, E.D. Mindfulness-Based Relapse Prevention and Transcranial Direct Current Stimulation to Reduce Heavy Drinking: A Double-Blind Sham-Controlled Randomized Trial. Alcohol Clin. Exp. Res. 2013, 37, 1296–1307. [CrossRef]

20. Zgierska, A.E.; Shapiro, J.; Burzinski, C.A.; Lerner, F.; Goodman-Strenske, V. Maintaining Treatment Fidelity of Mindfulness-Based Relapse Prevention Intervention for Alcohol Dependence: A Randomized Controlled Trial Experience. Evid Based Complement. Altern. Med. 2017, 2017, 971686. [CrossRef]

21. Bowden, S.; Chawla, N.; Collins, S.E.; Witkiewitz, K.; Hsu, S.; Grow, J.; Clifasefi, S.; Garner, M.; Douglass, A.; Larimer, M.E.; et al. Mindfulness-based relapse prevention for substance use disorders: A pilot efficacy trial. Subst. Abus. 2009, 30, 295–305. [CrossRef]

22. Von Hammerstein, C.; Khazaal, Y.; Dupuis, M.; Aubin, H.J.; Benyamina, A.; Luquiens, A.; Romo, L. Feasibility, acceptability and preliminary outcomes of a mindfulness-based relapse prevention program in a naturalistic setting among treatment-seeking patients with alcohol use disorder: A prospective observational study. BMJ Open 2019, 9, e026839. [CrossRef]

23. Grant, S.; Colaiaco, B.; Motala, A.; Shanman, R.; Booth, M.; Sorbero, M.; Hempel, S. Mindfulness-based Relapse Prevention for Substance Use Disorders: A Systematic Review and Meta-analysis. J. Addict. Med. 2017, 11, 386–396. [CrossRef]
24. Downs, S.H.; Black, N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J. Epidemiol Community Health* **1998**, *52*, 377–384. [CrossRef]

25. Livingston, J.D.; Milne, T.; Fang, M.L.; Amari, E. The effectiveness of interventions for reducing stigma related to substance use disorders: A systematic review. *Addiction* **2012**, *107*, 39–50. [CrossRef]

26. Glasner, S.; Mooney, L.J.; Ang, A.; Garneau, H.C.; Hartwell, E.; Brecht, M.L.; Rawson, R.A. Mindfulness-Based Relapse Prevention for Stimulant Dependent Adults: A Pilot Randomized Clinical Trial. *Mindfulness* **2017**, *8*, 126–135. [CrossRef]

27. Greenfield, B.L.; Roos, C.; Hagler, K.J.; Stein, E.; Bowen, S.; Witkiewitz, K.A. Race/ethnicity and racial group composition moderate the effectiveness of mindfulness-based relapse prevention for substance use disorder. *Addict. Behav.* **2018**, *81*, 96–103. [CrossRef]

28. Roos, C.; Bowen, S.; Witkiewitz, K. Approach Coping and Substance Use Outcomes Following Mindfulness-Based Relapse Prevention Among Individuals with Negative Affect Symptomatology. *Mindfulness* **2020**, *11*, 2397–2410. [CrossRef]

29. Zgierska, A.E.; Burzinski, C.A.; Mundt, M.P.; McClintock, A.S.; Cox, J.; Coe, C.L.; Miller, M.M.; Fleming, M.F. Mindfulness-based relapse prevention for alcohol dependence: Findings from a randomized controlled trial. *J. Subst. Abus. Treat.* **2019**, *100*, 96–103. [CrossRef]

30. Zullig, K.J.; Lander, L.R.; Sloan, S.; Brumage, M.R.; Hobbs, G.R.; Faulkenberry, L. Mindfulness-Based Relapse Prevention with Individuals Receiving Medication-Assisted Outpatient Treatment for Opioid Use Disorder. *Mindfulness* **2018**, *9*, 2397–2410. [CrossRef]

31. Foroushani, N. The impact of mindfulness-based relapse prevention on craving, lapse and mindfulness fostering in addicted patients in Methadone Maintenance Treatment. *Heroin Addict. Relat. Clin. Probl.* **2019**, *21*, 33–40.

32. Yaghubi, M.; Zargar, F.; Akbari, H. Comparing Effectiveness of Mindfulness-Based Relapse Prevention with Treatment as Usual on Impulsivity and Relapse for Methadone-Treated Patients: A Randomized Clinical Trial. *Addict. Health* **2017**, *9*, 156–165.

33. Yaghubi, M.; Zargar, F. Effectiveness of Mindfulness-based Relapse Prevention on Quality of Life and Craving in Methadone-treated Patients: A Randomized Clinical Trial. *Addict. Health* **2018**, *10*, 250–259. [CrossRef]

34. Zemestani, M.; Ottaviani, C. Effectiveness of Mindfulness-Based Relapse Prevention for Co-occurring Substance Use and Depression Disorders. *Mindfulness* **2016**, *7*, 1347–1355. [CrossRef]

35. Biseul, I.; Icick, R.; Seguin, P.; Bellivier, F.; Scott, J. Feasibility and Acceptability of the ‘HABIT’ Group Programme for Comorbid Bipolar and Alcohol and Substance use Disorders. *Clin. Psychol. Psychother.* **2017**, *24*, 887–898. [CrossRef] [PubMed]

36. Hölzel, B.K.; Lazar, S.W.; Gard, T.; Schuman-Olivier, Z.; Vago, D.R.; Ott, U. How Does Mindfulness Meditation Work? Proposing Mechanisms of Action From a Conceptual and Neural Perspective. *Perspect. Psychol. Sci.* **2011**, *6*, 537–559. [CrossRef] [PubMed]

37. Vago, D.R.; Silbersweig, D.A. Self-awareness, self-regulation, and self-transcendence (S-ART): A framework for understanding the neurobiological mechanisms of mindfulness. *Front. Hum. Neurosci.* **2012**, *6*, 296. [CrossRef] [PubMed]

38. Chiesa, A.; Serretti, A.; Jakobsen, J.C. Mindfulness: Top-down or bottom-up emotion regulation strategy? *Clin. Psychol. Rev.* **2013**, *33*, 82–96. [CrossRef]

39. Grecucci, A.; Pappaianni, E.; Siugzdaite, R.; Theuninck, A.; Job, R. Mindful Emotion Regulation: Exploring the Neurocognitive Mechanisms behind Mindfulness. *Biomed. Res. Int.* **2015**, *2015*, 670724. [CrossRef]

40. Riggs, N.R.; Greenberg, M.T.; Dvorakova, K. A Role for Mindfulness and Mindfulness Training in Substance Use Prevention. In Proceedings of the Third International Conference, MOD, Volterra, Italy, 10–13 September 2019; pp. 335–346. [CrossRef]

41. Palazidou, E. The neurobiology of depression. *Br. Med. Bull.* **2012**, *101*, 127–145. [CrossRef]